Abstract
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have